|
|
[Report]
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome - Reformulations set to drive near-term growth
Published: 2006/08
|
|
 |
|
|
|
|
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the CNS pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the Parkinson's disease and Restless Legs
Syndrome market
- CHAPTER 2 PATIENT POTENTIAL- PARKINSON'S DISEASE
- Definition of Parkinson's disease
- The etiology of PD is not yet clear
- Segmentation of Parkinson's disease
- Parkinson's disease is typically classified by the Hoehn & Yahr
scale
- Epidemiology of Parkinson's disease
- Demographics provide baseline sales growth
- Several comorbid disorders are thought to result from
neurodegeneration in PD
- Sleep disorders are most common in advanced PD
- Depression in PD has both psychological and pathological causes
- Dementia in PD becomes more likely as the disease progresses
- Psychosis is both a feature of PD and a side effect of treatment
- New tools are improving diagnosis
- Treatment strategies in Parkinson's disease
- Unmet needs in Parkinson's disease
- Drugs that slow or prevent disease progression
- Reduction of motor complications
- Motor fluctuations
- Dyskinesias
- Other motor complications
- Smoother levodopa dosage
- Lower side effects
- Reduce pill burden
- Reduce time to levodopa therapy
- Lower cost
- CHAPTER 3 PARKINSON'S DISEASE R&D APPROACH
- Classification of marketed and pipeline products
- Market definition for this report
- Dopaminergics
- Levodopa still considered most effective agent for reducing PD
symptoms
- Dopamine agonists
- Dopamine agonists considered first line therapy
- Mirapex (pramipexole) the market leading dopamine agonist
- Neupro (rotigotine CDS) offers an alternative delivery method
- Apokyn (apomorphine) helps niche patient cohort
- Several dopamine agonists with novel delivery systems are in
development
- Catechol-O-methyltransferase inhibitors
- Comtan (entacapone) is the market leading COMT-inhibitor
- Stalevo reduces pill burden
- Monoamine oxidase inhibitors
- Selegiline has an established role in the treatment of early PD
- Zelapar (selegiline; orally disintegrating tablets) may offer
advantages over conventional selegiline
- Azilect (rasagiline) has recently received approval for early and
late stage PD
- Safinamide is the only MAOI in late stage development
- Other marketed therapies
- Anticholinergics provide little interest for developers of new
treatments
- N-methlyl-D-aspartate receptor antagonists may hold further potential
- Novel therapies
- The potential for adenosine A2a receptor antagonists remains unclear
- Neuroprotectants aim to slow or stop the progression of PD
- Cell/ gene therapies are designed to make up for the loss of neurons
in PD
- Clinical trial design in Parkinson's disease
- Neuroprotection clinical trial design continues to present challenges
- At risk patients are ideal for studies but are difficult to recruit
- Choice of clinical endpoints in neuroprotective studies depends on
the population studied
- Futility studies help determine which agents to select for further
study
- Delayed start design aims to separate symptomatic from
neuroprotective effect of a study agent
- Clinical trial endpoints in Parkinson's disease
- Decreased latency to ON time, increased ON time, and decreased OFF
time are key endpoints for EU and US approval
- Unified Parkinson's Disease Rating Scale offers a more comprehensive
measure of PD progression
- Cognition, behavior and mood- Part I of the UPDRS
- Activities of daily living- Part II of the UPDRS
- Motor examination- Part III of the UPDRS
- Gold standard therapies for Parkinson's disease
- CHAPTER 4 PARKINSON'S DISEASE PIPELINE ANALYSIS
- Pipeline overview
- Late-stage pipeline overview
- Registration overview
- Pre-registration overview
- Phase III overview
- Phase II overview
- Key companies involved in the Parkinson's disease pipeline
- Big Pharma need to increase investment into drug discovery projects
for disease modifying agents
- The symptomatic treatment market provides opportunities for specialty
companies
- CHAPTER 5 DOPAMINERGICS- LATE-STAGE DRUG ANALYSIS AND FORECASTS
- Overview of the dopaminergic class
- V1512 (melevodopa-carbidopa)
- Drug overview
- Clinical trials
- Phase II/III trials conducted by Chiesi
- Ongoing Phase III trials
- Pharmacokinetic study
- Patient potential
- Marketing factors
- Further Datamonitor comments
- Satisfaction of unmet needs
- Reduction of dyskinesia or OFF time
- Smoother levodopa dosage
- Reduce pill burden
- Lower cost
- Forecasts to 2015
- Datamonitor does not expect V1512 to gain significant sales from
current treatments
- V1512 is at risk of generic entacapone from 2010
- CHAPTER 6 DOPAMINE AGONISTS- LATE-STAGE DRUG ANALYSIS AND FORECASTS
- Overview of the dopamine agonists class
- Requip Modutab (ropinirole XL 24 hour)
- Clinical trials
- Ongoing Phase III comparison with immediate release ropinirole
- Patient population
- Marketing factors
- Satisfaction of unmet needs
- Reduction of dyskinesia or OFF time
- Lower side effects
- Reduce pill burden
- Reduce time to levodopa therapy
- Lower cost
- Forecasts to 2015
- Datamonitor expects Requip Modutab to limit the success of Neupro
- Generic ropinirole is set to limit the success of Requip Modutab
- SLV-308
- Drug overview
- Ongoing Phase III clinical trials
- S308.3.001/ S308.3.003- SLV-308 in treatment of patients with early
PD
- Ascending dose tolerability/ safety study in advanced PD with
levodopa
- Patient potential
- Marketing factors
- Datamonitor comments
- Forecasts to 2015
- The role of SLV308 is not yet clear and forecast sales are low
- Other drugs in the dopamine agonist class
- Lisuride (TTS/ SubQ)
- Lisuride TTS
- Lisuride (SubQ)
- Datamonitor comments
- Rotigotine nasal spray
- Apomorphine nasal powder
- AMR-101 (apomorphine sublingual)
- CHAPTER 7 ADENOSINE A2A RECEPTOR ANTAGONISTS- LATE-STAGE DRUG ANALYSIS AND
FORECASTS
- Overview of the adenosine A2a receptor antagonist class
- KW-6002 (istradefylline)
- Drug overview
- Completed Phase III trials
- Study 6002-US-018- 10, 20, 40mg/day KW-6002 in combination
- Study 6002-US-013- 20mg/day KW-6002 in combination
- Study 6002-EU-007- 40mg/day KW-6002 in combination
- Completed Phase II trials
- Study 6002-US-001- 20, 40mg/day KW-6002 in combination
- Ongoing trials
- Study 6002-US-051- Phase II monotherapy in early PD
- Study 6002-0406- Phase II Japan- 20, 40mg/day KW-6002 in combination
- Study 6002-0407- Phase II Japan- early PD
- Study 6002-INT-001- long-term safety
- Study 6002-US-025- long-term safety
- Patient population
- Marketing factors
- Further Datamonitor comments
- Satisfaction of unmet needs
- Reduction of dyskinesia or OFF time
- Lower side effects
- Reduce pill burden
- Reduce time to levodopa therapy
- Lower cost
- Forecasts to 2015
- KW-6002 may provide a novel mechanism for treating 'wearing off'
- KW-6002 sales are expected to depend on the success of E2007
- Approval in Japan and use in early PD may support sales growth
- Other drugs in the adenosine A2a receptor antagonist class
- Fipamezole (JP-1730)
- Sch-58261 analog
- CHAPTER 8 MAOIS- LATE-STAGE DRUG ANALYSIS AND FORECASTS
- Overview of the MAOI class
- Safinamide (NW-1015)
- Drug overview
- Phase III clinical trials
- Adjunctive treatment to dopamine agonists in patients with
early-stage PD.
- Phase II trials
- Safinamide as an adjunct to a dopamine agonist in early PD.
- Phase I trials
- Patient potential
- Marketing factors
- Datamonitor comments
- Satisfaction of unmet needs
- Drugs that slow or prevent disease progression
- Reduction of dyskinesia or OFF time
- Reduce pill burden
- Lower cost
- Forecasts to 2015
- Safinamide's benefits over current MAOIs are unclear
- The ADAGIO study of Azilect will set the first hurdle for safinamide
in neuroprotection
- CHAPTER 9 NEUROPROTECTANTS- LATE STAGE DRUG ANALYSIS
- Overview of the neuroprotectant class
- Pipeline summary
- Definition of current comparator therapy
- SR57667
- Ongoing clinical trials
- EFC5287- Phase II study of SR57667 on the progression of PD
- ACT5288- Study of SR57667 on 18F-Dopa PET imaging in PD patients
- Further Datamonitor comments
- PD-02 (creatine)
- Phase II clinical trials
- Phase II futility study of PD-02 in early PD
- Cereact Capsule (ONO-2506PO)
- Drug overview
- Clinical trials
- Phase II study of ONO-2506PO in patients with PD in Japan.
- Datamonitor comments
- GM1 ganglioside
- Drug overview
- Clinical trials
- Phase II study of GM1 ganglioside in mild to moderate PD
- Second Phase II study of GM1 ganglioside in mild to moderate PD
- Kinampa (talampanel)
- Drug overview
- Clinical trials
- Phase II study of talampanel on dyskinesias associated with
treatment of patients with advanced PD
- NINDS sponsored Phase II study of talampanel
- FP-0011
- Late-stage development compounds recently discontinued
- GPI-1485
- Phase II study- Guildford Pharmaceuticals/ Amgen
- Phase II study- Guildford/ SNDC
- Phase II study- NINDS
- CHAPTER 10 CELL/GENE THERAPY- LATE STAGE PRODUCT ANALYSIS
- Overview of the cell/gene therapy class
- Pipeline summary
- Definition of current comparator therapy
- Spheramine (RPE cell therapy)
- Drug overview
- Clinical trials
- Phase I/II open-label study
- The STEPS trial- Phase II double-blind study
- Further Datamonitor comments
- AV201 (AAV-AADC)
- Drug overview
- Clinical trials
- Phase I/II increasing dose trial
- CHAPTER 11 OTHERS- LATE-STAGE DRUG ANALYSIS AND FORECASTS
- Overview of the others class
- E2007
- Drug overview
- Completed Phase II trials
- Study 204- Phase IIb proof-of-concept
- Ongoing Phase III trials
- Study E2007-E044-301- E2007 in levodopa treated PD patients with
motor fluctuations
- Patient potential
- Marketing factors
- Further Datamonitor comments
- Satisfaction of unmet needs
- Reduction of dyskinesia or OFF time
- Lower side effects
- Lower cost
- Forecasts to 2015
- E2007 is positioned as an alternative treatment for reducing OFF time
- Other drugs in the others class
- Tremode (zonisamide)
- Drug overview
- Clinical trials
- Forecast
- Keppra (levetiracetam)
- ACP-103
- Phase II study of ACP-103 on levodopa-induced dykinesias in PD
- Late-stage development compounds recently discontinued
- Sarizotan (EMD-128130)
- Drug overview
- Clinical trials
- Further Datamonitor comments
- Tesofensine (NS2330)
- Drug overview
- Clinical trials
- Datamonitor comments
- CHAPTER 12 INNOVATIVE EARLY-STAGE PARKINSON'S DISEASE PROJECTS
- Phase I and preclinical pipeline overview
- Phase I overview
- Preclinical overview
- Key Phase I and preclinical projects in PD
- Prosavin
- Alpha (α)-synuclein modulation
- CHAPTER 13 PATIENT POTENTIAL- RESTLESS LEGS SYNDROME
- Definition of Restless Legs Syndrome
- Segmentation of Restless Legs Syndrome
- Severity
- International Restless Legs Syndrome Study Group Rating Scale (IRLS).
- Comorbidities
- Epidemiology of Restless Legs Syndrome
- Treatment strategies in Restless Legs Syndrome
- Unmet needs in Restless Legs Syndrome
- Greater efficacy
- Faster onset of action
- Longer duration of action
- Improved side effect profile
- Effective second-line treatment
- Reduced frequency of dosing
- CHAPTER 14 RESTLESS LEGS SYNDROME R&D APPROACH
- Classification of marketed and pipeline products
- Market definition of Restless Legs Syndrome for this report
- Dopaminergic stimulation provides the mainstay of RLS treatment
- Dopamine agonists are the first-line choice
- Levodopa use is limited by the risk of augmentation
- Anticonvulsants are typically used in treatment resistant RLS
- Opioids can be useful for treatment resistant, painful RLS
- Sedatives may alleviate sleep disturbance
- Iron infusion poses a potential risk to RLS revenues
- Clinical trial design in Restless Legs Syndrome
- The IRLS is considered an essential primary efficacy measure
- Clinical Global Impression (CGI)
- Quality of life (QOL) measures
- Sleep disturbance
- Cardiovascular risks
- GSK's Requip (ropinirole)-the gold standard Restless Legs Syndrome
treatment
- Drug overview
- Completed Phase III trials
- Study design
- Results
- Long-term maintenance of efficacy
- Ongoing trials
- Study ROR104836
- TREAT RLS PRN
- Further Datamonitor comments
- Strategies for success
- CHAPTER 15 RESTLESS LEGS SYNDROME PIPELINE ANALYSIS
- Overview of treatments in development for Restless Legs Syndrome
- Requip XR (ropinirole extended release)
- Drug overview
- Phase III clinical trials
- US/EU Phase III study of Requip vs. Requip XR- 101468/204
- N. American Phase III study- 101468/205
- The ROX104805 Phase III study
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Longer duration of action
- Onset of action
- Forecasts to 2015
- Requip XR is expected to be eclipsed by Neupro
- Generic ropinirole is set to limit Requip XR revenues
- Transdermal rotigotine patch
- Drug overview
- Completed trials
- SP709- Phase II EU proof-of-concept study
- Open-label EU extension study
- Ongoing trials
- SP792- Phase III US study
- SP793- Open-label extension to SP792
- SP790- Phase III EU study
- SP794- EU sleep lab trial
- Patient potential
- Marketing factors
- Further Datamonitor comments
- Satisfaction of unmet needs
- Longer duration of action
- Faster onset of action
- Greater efficacy
- Forecasts to 2015
- Disadvantages associated with a patch formulation may limit sales
- XP13512
- Completed trials
- Ongoing trials
- XP052- US Phase III study
- XP053- US Phase III study
- XP060- US long-term withdrawal study
- XP055- US open-label extension study
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Greater efficacy
- Faster onset of action
- Duration of action
- Effective second-line treatment
- Improved side effect profile
- Forecasts to 2015
- XP13512 is expected to be positioned as an alternative to dopamine
agonists
- Other drugs for Restless Legs Syndrome
- Lisuride TTS
- KW-6002 (istradefylline)
- Safinamide
- Keppra (levetiracetam)
- Topamax (topiramate)
- BIBLIOGRAPHY
- APPENDIX
- Forecast revenues
- Methodology
- Datamonitor forecast methodology
- Product forecasts
- Sales calculations
- Definition of a standard unit
- Japanese market data
- Additional assumptions
- Report methodology
- Contributing experts
- About Datamonitor
- About Datamonitor Healthcare
- About the CNS analysis team
- Disclaimer
- List of Tables
- Table 1: The five stages of PD according to the Hoehn & Yahr scale
- Table 2: Prevalence of PD across the three major market regions, 2006
- Table 3: Diagnosed PD population in the US, Japan, and M5EU by severity
- Table 4: Key dopamine agonists
- Table 5: Study design in the assessment of pramipexole in early PD
- Table 6: Study design in the assessment of pramipexole in early PD
- Table 7: Adverse events occurring in >5% of early PD patients on
pramipexole as a monotherapy
- Table 8: Study design for pramipexole in advanced PD with levodopa
- Table 9: Key results from study of pramipexole vs. placebo in advanced
PD with levodopa
- Table 10: Adverse events occurring in >5% of advanced PD patients
treated with pramipexole in addition to levodopa
- Table 11: Number of adverse events occurring with Neupro vs. placebo
- Table 12: Study design in the assessment of rotigotine CDS in early PD
- Table 13: Key results from large scale studies of rotigotine CDS in
treating patients with early PD
- Table 14: Commonly occurring adverse events that were more frequent in
those treated with rotigotine than placebo
- Table 15: Results from the N. American study (SEESAW) of entacapone in
patients experiencing ON and OFF periods despite optimized levodopa therapy
- Table 16: Results from the Nordic study (NOMECOMT) of entacapone in
patients experiencing ON and OFF periods despite optimized levodopa therapy
- Table 17: Results from the German-Austrian study of entacapone in
patients taking levodopa-DDI and experiencing 'wearing off'
- Table 18: Adverse events occurring in ≥5% of entacapone patients
- Table 19: Pros and cons of neuroprotection study endpoints
- Table 20: Possible criteria for agent selection for neuroprotection
studies
- Table 21: Comparison of convention trial design versus the futility
trial design
- Table 22: Unified Parkinson's Disease Rating Scale : cognition,
behavior and mood
- Table 23: Number of R&D projects in each class split by phase of
development for PD, 2006
- Table 24: Compounds in registration for PD, 2006
- Table 25: Compounds in pre-registration for PD, 2006
- Table 26: Compounds in Phase III development for PD, 2006
- Table 27: Compounds in Phase II development for PD, 2006
- Table 28: Pfizer's R&D pipeline for PD treatments, 2006
- Table 29: Vernalis' R&D pipeline for PD treatments, 2006
- Table 30: Key products in late-stage development for the dopaminergic
class, 2006
- Table 31: Phase II studies of V1512 conducted by Chiesi
- Table 32: Phase III studies of V1512 conducted by Chiesi
- Table 33: Impacting factors on the sales of V1512, 2006-15
- Table 34: Key products in late-stage development for the dopamine
agonist class, 2006
- Table 35: Impacting factors on the sales of Requip Modutab, 2006-15
- Table 36: Impacting factors on the sales of SLV-308, 2006-15
- Table 37: Key products in late-stage development for the adenosine A2a
receptor antagonist class, 2006
- Table 38: Impacting factors on the sales of KW-6002, 2006-15
- Table 39: Key products in late-stage development for the MAOI class,
2006
- Table 40: Number of withdrawals and reasons given
- Table 41: Impacting factors on the sales of safinamide, 2006-15
- Table 42: Key products in late-stage development for the
neuroprotectant class, 2006
- Table 43: Patient characteristics at baseline
- Table 44: Change in UPDRS score from baseline to 12 months or the need
for symptomatic therapy (whichever first)
- Table 45: Discontinued projects in the neuroprotectant class, 2005-06
- Table 46: Key products in late-stage development for the cell/gene
therapy class, 2006
- Table 47: Key products in late-stage development for the others class,
2006
- Table 48: Impacting factors on the sales of E2007, 2006-15
- Table 49: Discontinued R&D projects in the 'others' class, 2005-06
- Table 50: Projects in Phase I development for PD, 2006
- Table 51: Projects in preclinical development for PD, 2006
- Table 52: Projects in preclinical development for PD, 2006 (continued)
- Table 53: Projects in preclinical development for PD, 2006 (continued)
- Table 54: The International Restless Legs Syndrome Study Group Rating
Scale (IRLS)
- Table 55: The prevalence of RLS in the US, M5EU and Japan, 2006
- Table 56: Dose titration schedule for ropinirole in treating RLS
- Table 57: Trial end points used in pivotal studies of Requip for RLS
- Table 58: TREAT RLS US study of ropinirole vs. placebo
- Table 59: TREAT RLS 1 study of ropinirole vs. placebo conducted in the
EU and other countries
- Table 60: TREAT RLS 2 study of ropinirole vs. placebo conducted in the
US and other countries
- Table 61: Products in development for RLS, 2006
- Table 62: Impacting factors on Requip XR RLS sales, 2006-15
- Table 63: Impacting factors on transdermal rotigotine RLS sales,
2006-15
- Table 64: Results of Phase IIb study
- Table 65: Impacting factors on XP13512 RLS sales, 2006-15
- Table 66: Forecast Parkinson disease drug revenues, 2006-2015
- Table 67: Forecast Restless Legs Syndrome drug revenues, 2006-2015
- Table 68: Parkinson's disease and Restless Legs Syndrome market
definition by ICD10 code
- List of Figures
- Figure 1: Projection of the population aged 65 or greater, across the
three major market regions, 2005-2050
- Figure 2: Current treatment pathway of PD patients as recommended by
guidelines
- Figure 3: Recommendations for management of Parkinson's disease
according to stage of disease
- Figure 4: Key unmet needs in Parkinson's disease treatment
- Figure 5: Unmet needs according to stage of disease
- Figure 6: Levodopa dose required to relieve symptoms compared to dose
required to induce dyskinesias
- Figure 7: Mechanism of action of AADC inhibitors (DDI)
- Figure 8: Results from the long-term study of Requip vs. levodopa on
the development of dyskinesia
- Figure 9: Key results from six month trial of pramipexole monotherapy
vs. placebo in treating patients with early PD
- Figure 10: Key results from mixed-dose study of pramipexole
monotherapy vs. placebo in treating patients with early PD
- Figure 11: Key results from study of pramipexole vs. placebo in
advanced PD with levodopa
- Figure 12: Neupro patch sizes and corresponding doses
- Figure 13: Change in UPDRS-II-III scores compared to placebo for
groups taking 2 to 8mg/24hrrotigotine
- Figure 14: UPDRS part II and III scores with Neupro vs. placebo
- Figure 15: Study SP512 results- comparison of rotigotine vs. placebo
in early PD over 24 weeks maintenance
- Figure 16: Study SP513 results - comparison of rotigotine vs.
ropinirole or placebo in early PD over 24 weeks maintenance
- Figure 17: Pooled results from three-randomized controlled clinical
trials evaluating efficacy of Apokyn
- Figure 18: Mechanism of action of COMT inhibitor, entacapone
- Figure 19: Key results from the N. American study (SEESAW) of
entacapone in patients experiencing ON and OFF periods despite optimized
levodopa therapy
- Figure 20: Key results from the Nordic study (NOMECOMT) of entacapone
in patients experiencing ON and OFF periods despite optimized levodopa
therapy
- Figure 21: Mechanism of action of MAO-B inhibitors
- Figure 22: Mean daily percentage awake OFF time with Zelapar (1.25 and
2.5mg/day) against placebo
- Figure 23: TEMPO study- change in UPDRS score with 1mg/day rasagiline
vs. placebo over six months
- Figure 24: TEMPO study- change in UPDRS score with rasagiline vs.
placebo over 12 months
- Figure 25: Change over 18 weeks in the LARGO study of rasagiline as an
adjunct to treatment in patients with moderate-to-advanced PD
- Figure 26: Change in daily ON time without troublesome dyskinesia over
18 weeks in the LARGO study of rasagiline as an adjunct to treatment in
patients with moderate-to-advanced PD
- Figure 27: Change in daily ON time with troublesome dyskinesia over 18
weeks in the LARGO study of rasagiline as an adjunct to treatment in
patients with moderate-to-advanced PD
- Figure 28: Change in daily OFF time over 26 weeks in the PRESTO study
of rasagiline as an adjunct to treatment in moderate-to-advanced PD
patients with motor complications
- Figure 29: Recommendations for management of Parkinson's disease
according to stage of disease
- Figure 30: Number of R&D projects at each stage of development,
2006
- Figure 31: Vernalis' inline and pipeline PD product range and where
they fit into the PD disease stages, 2006
- Figure 32: Depicts V1512's (CNP-1512) ability to reduce OFF time in
Phase II/III studies of PD patients experiencing motor fluctuations
- Figure 33: V1512's positioning against current unmet needs
- Figure 34: Forecast Parkinson's disease sales for V1512 across the US
and EU, 2006-2015
- Figure 35: Requip Modutab's positioning against current unmet needs
- Figure 36: Forecast Parkinson's disease sales for Requip Modutab
across the US and EU, 2006-2015
- Figure 37: Forecast Parkinson's disease sales for SLV-308 across the
US and EU, 2006-2015
- Figure 38: KW-6002's position against current unmet needs
- Figure 39: Datamonitor's forecast of KW-6002's revenues across the US,
EU and Japan ($m), 2006-2015
- Figure 40: UPDRS-III scores over the Phase II trials of safinamide in
a subset of patients also taking one dopamine agonist
- Figure 41: Safinamide's position against current unmet needs
- Figure 42: Datamonitor's forecast of safinamide's revenues across the
US, EU and Japan ($m), 2006-2015
- Figure 43: Participant flow in the Phase II study of PD-02 in early PD
- Figure 44: E2007 proof-of-concept Phase II trial results
- Figure 45: E2007's position against current unmet needs
- Figure 46: Datamonitor's forecast of E2007's revenues across the US,
EU and Japan ($m), 2006-2015
- Figure 47: Phase II trial results of NS2330 in advanced PD
- Figure 48: Results showing the effects of ProSavin in MPTP-treated
primates
- Figure 49: The proportion of individuals with RLS classified as having
a medically significant diagnosis
- Figure 50: The prevalence of RLS in the EU by age group
- Figure 51: Key unmet needs in RLS treatment
- Figure 52: Change in IRLS total score over 12 weeks (pooled results
from the three pivotal studies used for US filing)
- Figure 53: Most common adverse events reported in patients treated
with ropinirole in TREAT RLS trials
- Figure 54: Unmet needs associated with Requip
- Figure 55: Requip XR's potential advantages over current treatments
- Figure 56: Forecast RLS sales for Requip XR across the US and EU,
2006-2015
- Figure 57: Transdermal rotigotine's potential advantages over current
treatments
- Figure 58: Forecast RLS sales for transdermal rotigotine across the US
and EU, 2006-2015
- Figure 59: XP13512's potential advantages over current treatments
- Figure 60: Forecast RLS sales for XP13512 across the US, EU and Japan
2006-2015
|
|
|
|
|
|
|
|
[Report]
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome - Reformulations set to drive near-term growth
Published: 2006/08
|
Published by : Datamonitor  |
|
|
Price:
|
Product Code : DC43894 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
